March Altus Capital Management’s United Therapeutics UTHR Stock Holding History

March Altus Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-2,500	Closed	-$328K	–	13
2015 Q3	$328K	Sell	2,500 -7,509	-75%	-$1.2M	1.93%	14
2015 Q2	$1.74M	Sell	10,009 -799	-7%	-$144K	10.12%	2
2015 Q1	$1.86M	Sell	10,808 -104,269	-91%	-$15.9M	11.72%	1
2014 Q4	$14.9M	Sell	115,077 -54,475	-32%	-$7.02M	6.81%	1
2014 Q3	$21.8M	Sell	169,552 -74,521	-31%	-$7.68M	8.68%	1
2014 Q2	$21.6M	Buy	244,073 +77,348	+46%	+$7.44M	7.91%	1
2014 Q1	$15.7M	Buy	+166,725	New	+$17.1M	5.03%	5

Other funds holding UTHR

ACM

Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

March Altus Capital Management's UTHR Position: Q4 2015 in Review

March Altus Capital Management sold out of United Therapeutics (UTHR) in Q4 2015, closing a stake of 2,500 shares — an estimated $328K sold.

March Altus Capital Management first reported a position in UTHR in Q1 2014 and held it in 7 quarters. The position peaked at $21.8M in Q3 2014. 386 funds tracked by Wall St. Rank hold UTHR as of Q4 2015.

March Altus Capital Management reported no remaining United Therapeutics position as of Q4 2015 after selling out during the quarter.
March Altus Capital Management sold 2,500 United Therapeutics shares in Q4 2015, an estimated $328K.
March Altus Capital Management first reported a position in United Therapeutics in Q1 2014 and held it in 7 quarters.
March Altus Capital Management's United Therapeutics position peaked at $21.8M in Q3 2014.
386 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2015.

Based on March Altus Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.